{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T19:47:51Z","timestamp":1781552871650,"version":"3.54.5"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T00:00:00Z","timestamp":1739318400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"},{"start":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T00:00:00Z","timestamp":1739318400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"}],"funder":[{"DOI":"10.13039\/501100006211","name":"Humboldt-Universit\u00e4t zu Berlin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006211","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Hintergrund<\/jats:title>\n                    <jats:p>Klinische Studien mit Psilocybin in Kombination mit Psychotherapie zeigen vielversprechende Ergebnisse bei der Behandlung verschiedener psychischer St\u00f6rungen. In der \u00c4rzte- und Psychotherapeutenschaft sowie unter Patient:innen bestehen auch Unwissen, Ablehnung und Vorurteile gegen\u00fcber dieser neuen Therapieform. Ziel dieser Studie war es, einen m\u00f6glichst repr\u00e4sentativen Eindruck vom Informationsstand und der Einstellung zur Implementation psilocybin-assistierter Therapie (PAT) unter Expert:innen f\u00fcr psychische Gesundheit sowie Patient:innen und der Allgemeinbev\u00f6lkerung zu erheben.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methodik<\/jats:title>\n                    <jats:p>Mittels einer Onlineumfrage wurden Informationen zu Einstellungen und Kenntnisstand von 1456 Teilnehmenden, darunter \u00c4rzt:innen, Psychotherapeut:innen und Patient:innen, erfasst sowie Effekte der experimentellen Gabe von Informationen zu Potenzialen und Risiken getestet. Ergebnisse wurden mittels Varianzanalysen und Regressionsmodellen ermittelt.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ergebnisse<\/jats:title>\n                    <jats:p>\n                      Regressionsanalysen zeigten, dass ein h\u00f6herer Kenntnisscore und selbsteingesch\u00e4tzter Kenntnisstand, eigene Behandlungserfahrung, aber auch eigene Erfahrung mit Psychedelika positivere Einstellungen bez\u00fcglich der Einf\u00fchrung von PAT vorhersagten (\n                      <jats:italic>F<\/jats:italic>\n                      [8, 1447]\u202f=\u2009154,646,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&lt;\u20090,001, R\n                      <jats:sup>2<\/jats:sup>\n                      \u202f=\u20090,39). Die Vermittlung von Informationen \u00fcber die Potenziale von PAT f\u00fchrte dann zu einer h\u00f6heren Akzeptanz, wenn diese mit Informationen \u00fcber deren Risiken kombiniert wurden.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diskussion<\/jats:title>\n                    <jats:p>Die Ergebnisse zeigen, dass Teilnehmende einer Einf\u00fchrung psilocybin-assistierter Therapie optimistisch gegen\u00fcberstehen. Der Zusammenhang zwischen Wissen und Akzeptanz wurde best\u00e4tigt. Dass die Vermittlung ausgeglichener Informationen zu h\u00f6herer Akzeptanz f\u00fchrt, sollte bei der Aufkl\u00e4rung und Berichterstattung \u00fcber PAT ber\u00fccksichtigt werden.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00115-024-01792-5","type":"journal-article","created":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T10:00:45Z","timestamp":1739354445000},"page":"582-589","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Akzeptanz psilocybin-assistierter Therapie in den deutschsprachigen L\u00e4ndern","Acceptance of psilocybin-assisted therapy in German-speaking countries"],"prefix":"10.1007","volume":"96","author":[{"given":"Nina","family":"Hartter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marvin","family":"D\u00e4umichen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Wolff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Gr\u00fcnder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Jungaberle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,12]]},"reference":[{"key":"1792_CR1","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1007\/s00278-024-00711-y","volume":"69","author":"H Aicher","year":"2024","unstructured":"Aicher\u00a0H, Schmid\u00a0Y, Gasser\u00a0P (2024) Psychedelika-assistierte Psychotherapie. Die Psychother 69:98\u2013106","journal-title":"Die Psychother"},{"key":"1792_CR2","first-page":"e45169","volume":"15","author":"AN Bhuiya","year":"2023","unstructured":"Bhuiya\u00a0AN, Jacobs\u00a0RJ, Wang\u00a0K et\u00a0al (2023) Predictors of Medical Students\u2019 Perceptions of Psilocybin-Assisted Therapy for Use in Medical Practice. Cureus 15:e45169","journal-title":"Cureus"},{"key":"1792_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/psymed.2023.0036","volume":"2","author":"BS Barnett","year":"2024","unstructured":"Barnett\u00a0BS, Arakelian\u00a0M, Beebe\u00a0D et\u00a0al (2024) American Psychiatrists\u2019 Opinions About Classic Hallucinogens and Their Potential Therapeutic Applications: A\u00a07-Year Follow-Up Survey. Psychedelic Med 2:1\u20139","journal-title":"Psychedelic Med"},{"key":"1792_CR4","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1097\/NMD.0000000000000828","volume":"206","author":"BS Barnett","year":"2018","unstructured":"Barnett\u00a0BS, Siu\u00a0WO, Pope\u00a0HG Jr (2018) A survey of American psychiatrists\u2019 attitudes toward classic hallucinogens. J\u00a0Nerv Ment Dis 206:476\u2013480","journal-title":"J Nerv Ment Dis"},{"key":"1792_CR5","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1177\/02698811221116926","volume":"36","author":"JJ Breeksema","year":"2022","unstructured":"Breeksema\u00a0JJ, Kuin\u00a0BW, Kamphuis\u00a0J et\u00a0al (2022) Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A\u00a0mixed-methods systematic review. J\u00a0Psychopharmacol 36:1100\u20131117","journal-title":"J Psychopharmacol"},{"key":"1792_CR6","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","volume":"384","author":"R Carhart-Harris","year":"2021","unstructured":"Carhart-Harris\u00a0R, Giribaldi\u00a0B, Watts\u00a0R et\u00a0al (2021) Trial of psilocybin versus escitalopram for depression. N\u00a0Engl J Med 384:1402\u20131411","journal-title":"N Engl J Med"},{"key":"1792_CR7","first-page":"220","volume-title":"The Sage handbook of persuasion","author":"J Compton","year":"2013","unstructured":"Compton\u00a0J (2013) Inoculation Theory. In: Dillard\u00a0JP, Shen\u00a0L (Hrsg) The Sage handbook of persuasion. SAGE, California, S\u00a0220\u2013236"},{"issue":"191","key":"1792_CR8","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1007\/s11845-021-02668-2","volume":"1971","author":"K Corrigan","year":"2022","unstructured":"Corrigan\u00a0K, Haran\u00a0M, Mccandliss\u00a0C et\u00a0al (2022) Psychedelic perceptions: mental health service user attitudes to psilocybin therapy. Ir J Med Sci 1971(191):1385\u20131397","journal-title":"Ir J Med Sci"},{"key":"1792_CR9","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1080\/02791072.2021.1971343","volume":"54","author":"AK Davis","year":"2022","unstructured":"Davis\u00a0AK, Agin-Liebes\u00a0G, Espa\u00f1a\u00a0M et\u00a0al (2022) Attitudes and beliefs about the therapeutic use of psychedelic drugs among psychologists in the United States. J\u00a0Psychoactive Drugs 54:309\u2013318","journal-title":"J Psychoactive Drugs"},{"key":"1792_CR10","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3390\/bs13040297","volume":"13","author":"JJ Dawood Hristova","year":"2023","unstructured":"Dawood Hristova\u00a0JJ, P\u00e9rez-Jover\u00a0V (2023) Psychotherapy with psilocybin for depression: Systematic review. Behav Sci 13:297","journal-title":"Behav Sci"},{"key":"1792_CR11","doi-asserted-by":"publisher","first-page":"157","DOI":"10.2174\/1874473708666150107121331","volume":"7","author":"A Garcia-Romeu","year":"2014","unstructured":"Garcia-Romeu\u00a0A, Griffiths\u00a0RR, Johnson\u00a0WM (2014) Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. CDAR 7:157\u2013164","journal-title":"CDAR"},{"key":"1792_CR12","doi-asserted-by":"publisher","first-page":"112749","DOI":"10.1016\/j.psychres.2020.112749","volume":"284","author":"SB Goldberg","year":"2020","unstructured":"Goldberg\u00a0SB, Pace\u00a0BT, Nicholas\u00a0CR et\u00a0al (2020) The experimental effects of psilocybin on symptoms of anxiety and depression: A\u00a0meta-analysis. Psychiatry Res 284:112749","journal-title":"Psychiatry Res"},{"key":"1792_CR13","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1055\/a-1486-7386","volume":"54","author":"G Gr\u00fcnder","year":"2021","unstructured":"Gr\u00fcnder\u00a0G, Jungaberle\u00a0H (2021) The potential role of psychedelic drugs in mental health care of the future. Pharmacopsychiatry 54:191\u2013199","journal-title":"Pharmacopsychiatry"},{"key":"1792_CR14","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1002\/jcad.12429","volume":"100","author":"BG Hearn","year":"2022","unstructured":"Hearn\u00a0BG, Brubaker\u00a0MD, Richardson\u00a0G (2022) Counselors\u2019 attitudes toward psychedelics and their use in therapy. J\u00a0Couns Dev 100:364\u2013373","journal-title":"J Couns Dev"},{"key":"1792_CR15","first-page":"122","volume-title":"The Elephant in the Room: Personal use of psychedelics among psychedelic researchers","author":"PS Hendricks","year":"2023","unstructured":"Hendricks\u00a0PS, Nichols\u00a0CD (2023) The Elephant in the Room: Personal use of psychedelics among psychedelic researchers. Mary Ann Liebert, Inc, S\u00a0122\u2013123"},{"key":"1792_CR16","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1055\/a-2233-4301","volume":"43","author":"U Herwig","year":"2024","unstructured":"Herwig\u00a0U (2024) Psychedelika in der Psychiatrie. Nervenheilkunde 43:236\u2013241","journal-title":"Nervenheilkunde"},{"key":"1792_CR17","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1007\/s13311-017-0542-y","volume":"14","author":"MW Johnson","year":"2017","unstructured":"Johnson\u00a0MW, Griffiths\u00a0RR (2017) Potential therapeutic effects of psilocybin. Neurotherapeutics 14:734\u2013740","journal-title":"Neurotherapeutics"},{"key":"1792_CR18","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.neuropharm.2018.05.012","volume":"142","author":"MW Johnson","year":"2018","unstructured":"Johnson\u00a0MW, Griffiths\u00a0RR, Hendricks\u00a0PS et\u00a0al (2018) The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act. Neuropharmacology 142:143\u2013166","journal-title":"Neuropharmacology"},{"key":"1792_CR19","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/978-3-642-55125-3_1","volume-title":"Handbuch Psychoaktive Substanzen","author":"H Jungaberle","year":"2018","unstructured":"Jungaberle\u00a0H, Biedermann\u00a0N, Nott\u00a0J et\u00a0al (2018) Salutogene und nicht-pathologische Formen von Substanzkonsum. In: Handbuch Psychoaktive Substanzen, S\u00a0175\u2013196"},{"key":"1792_CR20","doi-asserted-by":"crossref","unstructured":"Jungwirth J, Bavato F, Quednow BB (2024) Psychedelika und Dissoziativa in der Psychiatrie: Herausforderungen in der Behandlung. Nervenarzt: 1\u20138","DOI":"10.1007\/s00115-024-01744-z"},{"key":"1792_CR21","unstructured":"Leiner DJ (2024) SoSci Survey (Version 3.5.02). https:\/\/www.soscisurvey.de"},{"key":"1792_CR22","doi-asserted-by":"publisher","first-page":"1190507","DOI":"10.3389\/fpsyt.2023.1190507","volume":"14","author":"I Li","year":"2023","unstructured":"Li\u00a0I, Fong\u00a0R, Hagen\u00a0M et\u00a0al (2023) Medical student attitudes and perceptions of psychedelic-assisted therapies. Front Psychiatry 14:1190507","journal-title":"Front Psychiatry"},{"key":"1792_CR23","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1037\/h0048344","volume":"63","author":"WJ Mcguire","year":"1961","unstructured":"Mcguire\u00a0WJ (1961) Resistance to persuasion conferred by active and passive prior refutation of the same and alternative counterarguments. J\u00a0Abnorm Soc Psychol 63:326","journal-title":"J Abnorm Soc Psychol"},{"key":"1792_CR24","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.jad.2022.12.050","volume":"323","author":"P Meir","year":"2023","unstructured":"Meir\u00a0P, Taylor\u00a0L, Soares\u00a0JC et\u00a0al (2023) Psychotherapists\u2019 openness to engage their patients in Psilocybin-Assisted Therapy for mental health treatment. J\u00a0Affect Disord 323:748\u2013754","journal-title":"J Affect Disord"},{"key":"1792_CR25","doi-asserted-by":"publisher","first-page":"100104","DOI":"10.1016\/j.nsa.2022.100104","volume":"1","author":"LJ Mertens","year":"2022","unstructured":"Mertens\u00a0LJ, Koslowski\u00a0M, Betzler\u00a0F et\u00a0al (2022) Methodological challenges in psychedelic drug trials: Efficacy and safety of psilocybin in treatment-resistant major depression (EPIsoDE)\u2014Rationale and study design. Neurosci Appl 1:100104","journal-title":"Neurosci Appl"},{"key":"1792_CR26","doi-asserted-by":"publisher","first-page":"114727","DOI":"10.1016\/j.psychres.2022.114727","volume":"316","author":"TD Meyer","year":"2022","unstructured":"Meyer\u00a0TD, Meir\u00a0P, Lex\u00a0C et\u00a0al (2022) Magic mushrooms\u2014an exploratory look at how mental health professionals feel and think about psilocybin. Psychiatry Res 316:114727","journal-title":"Psychiatry Res"},{"key":"1792_CR27","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1080\/17512433.2021.1933434","volume":"14","author":"SD Muthukumaraswamy","year":"2021","unstructured":"Muthukumaraswamy\u00a0SD, Forsyth\u00a0A, Lumley\u00a0T (2021) Blinding and expectancy confounds in psychedelic randomized controlled trials. Expert Rev Clin Pharmacol 14:1133\u20131152","journal-title":"Expert Rev Clin Pharmacol"},{"key":"1792_CR28","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1124\/pr.115.011478","volume":"68","author":"DE Nichols","year":"2016","unstructured":"Nichols\u00a0DE (2016) Psychedelics. Pharmacol Rev 68:264\u2013355","journal-title":"Pharmacol Rev"},{"key":"1792_CR29","first-page":"80","volume":"91","author":"C Schmidt","year":"2023","unstructured":"Schmidt\u00a0C, Wolff\u00a0M, Gr\u00fcnder\u00a0G et\u00a0al (2023) Einstellungen von Expertinnen und Experten f\u00fcr psychische Gesundheit gegen\u00fcber Psilocybin. Fortschritte der Neurologie. Psychiatrie 91:80\u201387","journal-title":"Psychiatrie"},{"key":"1792_CR30","unstructured":"Spangemacher\u00a0M, Mertens\u00a0LJ, F\u00e4rber\u00a0LV, Jungaberle\u00a0A, Jungaberle\u00a0H, Gr\u00fcnder\u00a0G (2024) Psilocybin als krankheitsmodifizierendes Arzneimittel. Ein salutogenetischer Ansatz in der Psychiatrie. Dtsch Arztebl Int 121:868\u2013874"},{"key":"1792_CR31","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/978-3-642-55125-3_3","volume-title":"Handbuch Psychoaktive Substanzen","author":"J Ullrich","year":"2018","unstructured":"Ullrich\u00a0J (2018) Sucht, Abh\u00e4ngigkeit und sch\u00e4dlicher Gebrauch: Klassifikationen und Erkl\u00e4rungsans\u00e4tze. In: Handbuch Psychoaktive Substanzen, S\u00a0207\u2013215"},{"key":"1792_CR32","doi-asserted-by":"publisher","first-page":"18716","DOI":"10.1038\/s41598-024-69688-7","volume":"14","author":"MF \u017duljevi\u0107","year":"2024","unstructured":"\u017duljevi\u0107\u00a0MF, Hren\u00a0D, Storman\u00a0D et\u00a0al (2024) Attitudes of European psychiatrists on psychedelics: a\u00a0cross-sectional survey study. Sci Rep 14:18716","journal-title":"Sci Rep"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-024-01792-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00115-024-01792-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-024-01792-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T15:39:57Z","timestamp":1762270797000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00115-024-01792-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,12]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1792"],"URL":"https:\/\/doi.org\/10.1007\/s00115-024-01792-5","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,12]]},"assertion":[{"value":"4 November 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"G.\u00a0Gr\u00fcnder war in den letzten drei Jahren als Berater f\u00fcr Boehringer Ingelheim (Ingelheim, Deutschland), das Institut f\u00fcr Qualit\u00e4t und Wirtschaftlichkeit im Gesundheitswesen (IQWiG, K\u00f6ln, Deutschland), Janssen-Cilag (Neuss, Deutschland), Lundbeck (Kopenhagen, D\u00e4nemark), MindMed (New York, USA), Otsuka (Chiyoda, Japan), Recordati (Mailand, Italien), Roche (Basel, Schweiz) und ROVI (Madrid, Spanien) t\u00e4tig. Er war als Referent f\u00fcr Gedeon Richter (Budapest, Ungarn), Janssen Cilag, Lundbeck, Otsuka und Recordati t\u00e4tig. Er erhielt Forschungsunterst\u00fctzung von Beckley Psytech (London, UK) und Boehringer Ingelheim. Er ist Mitgr\u00fcnder und\/oder Gesellschafter der Mind and Brain Institute GmbH (Zornheim, Deutschland), der OVID Health Systems GmbH (Berlin, Deutschland), der OVID Clinic Berlin GmbH und der MIND Foundation gGmbH (Berlin, Deutschland). Er ist stellv. Vorsitzender der Deutschen Gesellschaft f\u00fcr Psychedelische Therapie und Forschung (DGPFT). H.\u00a0Jungaberle ist Mitbegr\u00fcnder und Gesellschafter von OVID Health Systems, der OVID Clinic Berlin und des Non-Profits MIND Foundation. M.\u00a0Wolff und C.\u00a0Schmidt arbeiten bei der MIND Foundation.N.\u00a0Hartter und M.\u00a0D\u00e4umichen geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Die Studie wurde von der Ethikkommission der \u00c4rztekammer Berlin gepr\u00fcft und genehmigt (Eth-22\/23).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}